Stock Analysis

Crescita Therapeutics Full Year 2022 Earnings: EPS: CA$0.042 (vs CA$0.053 loss in FY 2021)

Source: Shutterstock

Crescita Therapeutics (TSE:CTX) Full Year 2022 Results

Key Financial Results

  • Revenue: CA$23.5m (up 40% from FY 2021).
  • Net income: CA$862.0k (up from CA$1.11m loss in FY 2021).
  • Profit margin: 3.7% (up from net loss in FY 2021).
  • EPS: CA$0.042 (up from CA$0.053 loss in FY 2021).
TSX:CTX Earnings and Revenue History March 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Crescita Therapeutics shares are up 1.4% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Crescita Therapeutics has 2 warning signs we think you should be aware of.

Valuation is complex, but we're helping make it simple.

Find out whether Crescita Therapeutics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis